NasdaqGS:INCYBiotechs
Should Positive DLBCL Data And New IO Collaboration Require Action From Incyte (INCY) Investors?
Incyte has reported positive Phase 3 results for tafasitamab (Monjuvi/Minjuvi) in first-line diffuse large B-cell lymphoma, with full data to be presented at the 2026 ASCO Annual Meeting, supporting global regulatory submissions, and separately entered a clinical collaboration with Adagene to test a novel combination therapy in microsatellite stable colorectal cancer in a Phase 1 trial planned for 2026.
These advances highlight Incyte’s effort to broaden its oncology portfolio beyond...